Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) is now approved in the EU for use in all indications of reference...
FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active controlSAN DIEGO, April 01, 2023...
DENVER, March 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"),...
LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical...
Toronto, Ontario--(Newsfile Corp. - March 30, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company") today announced that...
Crystal Lake, Illinois--(Newsfile Corp. - March 30, 2023) - A unique and largely unknown niche is being launched by Shepherd...
Equity proceeds of CA$22M+ raised during 2022 fiscal yearPhase 1 clinical trial dosing of proprietary compound, NVG-291, is complete and...
Toronto, Ontario--(Newsfile Corp. - March 29, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company") today announced that...
Calgary, Alberta--(Newsfile Corp. - March 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")...
MALVERN, Pa., March 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in...
WALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...
REDWOOD CITY, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on development...
Achieved record revenue of $36.2 million, representing 21% increase over the year 2021 Company to host conference call and webcast...
-- Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led by Frazier Healthcare Partners and...
If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure...
NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Committee for Medicinal Products for Human...
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in...
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023...
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, March 31, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),...